Samsung Biologics Co Ltd (Samsung Biologics) provides contract manufacturing services for the production of biopharmaceuticals. The company offers discovery and development services, non-GMP DS and cGMP DS DP production services, clinical manufacturing services and biosafety and analytical testing services, among others. It also offers fill and finish services. Samsung Biologics technology platform includes S-CHOice-high-performing cho-k1-based cell line development platform, S-DUAL - bispecific antibody platform and DEVELOPICK - developability assessment platform. The company owns manufacturing facilities for cell culture development, purification, quality control, and MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.
Headquarters
South Korea
Address
300, Songdo Bio-Daero, Yeonsu-Gu, Incheon, 21987
Website
samsungbiologics.com
Telephone
82 32 4553114
No of Employees
2,587
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
207940 (KRX)
Revenue (2022)
$2.8B
23.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
7.5%
(2022 vs 2021)
Market Cap*
$41.6B
Net Profit Margin (2022)
XYZ
-12.7%
(2022 vs 2021)
* As of and is in US$
Samsung Biologics Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Platforms: | Discovery and Development Services | S-DUAL |
| S-CHOice-High-performing CHO-K1-based Cell Line Development Platform | Non-GMP DS and cGMP DS DP Production Services | DEVELOPICK |
| S-DUAL - Bispecific Antibody Platform | Clinical Manufacturing Services | S-CHOice |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Rapid Micro Biosystems to use the Growth Direct platform to automate its microbial quality control processes. |
| 2023 | Contracts/Agreements | In October, the company entered into a partnership with Kurma Partners for the development and manufacturing of biologics for Kurma Partners' portfolio companies. |
| 2023 | Contracts/Agreements | In June, the company and Pfizer entered into a partnership for the commercial manufacturing of Pfizer’s multi-product portfolio. |
Competitor Comparison
| Key Parameters | Samsung Biologics Co Ltd | Celltrion Healthcare Co Ltd | ToolGen Inc | Ensol Biosciences Inc | HLB Science Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Incheon | Incheon | Seoul | Daejeon | Seoul |
| State/Province | - | - | Seoul | - | - |
| No. of Employees | 2,587 | - | 85 | 41 | 13 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Rim | Chief Executive Officer; Chairman; President | Executive Board | 2020 | 62 |
| Kun Lo | Director; Executive Vice President; Head - EPCV Center | Executive Board | 2020 | - |
| Dongjoong Kim | Chief Financial Officer; Executive Vice President | Senior Management | - | - |
| James Choi | Executive Vice President; Chief Marketing Officer; Head - Sales Support Center | Senior Management | - | - |
| Christina Kim | Head - Business Development Team; Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward